Universal Type A Influenza Program

About EnGen Bio

EnGen Bio is a preclinical-stage biotech developing a universal Type A influenza vaccine and antibody therapy targeting a novel, highly conserved epitope on the M1 matrix protein. The company has generated promising preclinical data demonstrating broad neutralization and protection in animal models, supported by a foundational IP portfolio of nine patents. While still early-stage, its technology addresses a significant unmet need for pandemic preparedness and seasonal flu, attracting interest and funding from major government and philanthropic organizations.

Therapeutic Areas